Algernon NeuroScience (AGN Neuro) is a wholly owned private subsidiary of Algernon Pharmaceuticals (Algernon Pharma), and has been established to advance Algernon Pharma’s psychedelic DMT program for stroke and traumatic brain injury (TBI). (make these links to the Pipeline section)
There are more than 12.2 million new strokes each year globally, with 7.6 million (62%) of these being ischemic, meaning a clot blocks blood flow to the brain. The balance are hemorrhagic strokes where there is bleeding in the brain. There are 6.5 million people who die from stroke annually, with one in four people over the age of 25 expected to have a stroke in their lifetime. Over 63 million years of healthy life is lost each year due to ischemic stroke-related death and disability. 1
According to the National Institute of Neurological Disorders and Stroke, a TBI can be caused by a forceful bump, blow, or jolt to the head or body, or from an object that pierces the skull and enters the brain. Not all blows or jolts to the head result in a TBI. Some types of TBI can cause temporary or short-term problems with normal brain function, including problems with how the person thinks, understands, moves, communicates, and acts. More serious TBI can lead to severe and permanent disability, and even death. 2
Algernon Pharma is a clinical stage, Canadian drug development and repurposing company investigating multiple drugs for unmet global medical needs. In addition to the psychedelic DMT program for stroke and traumatic brain injury recovery being run by AGN Neuro, Algernon Pharma is also investigating Ifenprodil for chronic cough and idiopathic pulmonary fibrosis, as well as Repirinast for chronic kidney disease. For more information about these programs and Algernon Pharma please visit www.algernonpharmaceuticals.com.